Who is sponsoring NCT06245915?

NCT06245915 is sponsored by Arsenal Biosciences, Inc..

What drugs are being tested in NCT06245915?

Interventions in NCT06245915: AB-2100.

What condition does NCT06245915 study?

NCT06245915 studies Advanced/Metastatic Clear Cell Renal Cell Carcinoma, Recurrence.

Is NCT06245915 still recruiting?

NCT06245915 is currently active, enrolled. Last updated 22 September 2025.

Last reviewed 2025-09-22 · How we verify

NCT06245915

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

AB-2100, an Integrated Circuit T Cell Therapy in Patients With Recurrent Clear-cell Renal Cell Carcinoma (ccRCC)

Active, enrolled Phase 1, PHASE2 Last updated 22 September 2025

What this trial tests

Phase 1, PHASE2 trial testing AB-2100 in Advanced/Metastatic Clear Cell Renal Cell Carcinoma in 37 participants. Participants enrolled and being followed up; not accepting new ones.

Timeline

26 February 2024

Primary endpoint
31 March 2026

30 June 2028

Quick facts

Lead sponsor	Arsenal Biosciences, Inc.
Phase	Phase 1, PHASE2
Status	Active, enrolled
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	treatment
Enrollment	37
Start date	26 February 2024
Primary completion	31 March 2026
Estimated completion	30 June 2028
Sites	9 locations across United States

Drugs / interventions tested

AB-2100 — full drug profile →

Conditions studied

Advanced/Metastatic Clear Cell Renal Cell Carcinoma — all drugs for Advanced/Metastatic Clear Cell Renal Cell Carcinoma →
Recurrence — all drugs for Recurrence →

Sponsor

Arsenal Biosciences, Inc. — full company profile →

Who can join

18 and older, any sex, with Advanced/Metastatic Clear Cell Renal Cell Carcinoma or Recurrence. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This is a multi-center, open-label phase 1/2 trial evaluating the safety and efficacy of AB-2100 cell product. The study may enroll approximately 60 patients in phase 1 and approximately 70 patients in phase 2.

Publications & conference data

4 peer-reviewed publications reference this trial (live from Europe PMC):

Engineering strategies to safely drive CAR T-cells into the future.
Rossi M, Breman E. · · 2024 · cited 25× · PMID 38962002 · DOI 10.3389/fimmu.2024.1411393
CAR-engineered lymphocyte persistence is governed by a FAS ligand-FAS autoregulatory circuit.
Yi F, Cohen T, Zimmerman N, Dündar F, et al · · 2025 · cited 17× · PMID 40696154 · DOI 10.1038/s43018-025-01009-x
From Bench to Bedside: Emerging Paradigms in CAR-T Cell Therapy for Solid Malignancies.
Chen Y, Ren R, Yan L, Zhou Y, et al · · 2025 · cited 6× · PMID 40855662 · DOI 10.1002/advs.202505822
Enhancing the safety and efficacy of cell therapy with programmed sense-and-respond function.
Walters AJ, Yang X, Olson SD, Bashor CJ. · · 2025 · PMID 40292750 · DOI 10.1002/ctm2.70328

Verify or expand the search:

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT06245915 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Arsenal Biosciences, Inc.
Last refreshed: 22 September 2025

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06245915.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing